Influenza A/H1N1 vaccination response is inadequate in down syndrome children when the latest cut-off values are used

Area of Science:

• Immunology
• Pediatrics
• Genetics

Background:

• Down syndrome is associated with an increased risk of infections.
• Influenza A/H1N1 poses a significant health threat to vulnerable populations.
• Understanding vaccine efficacy in children with Down syndrome is crucial for public health.

Purpose of the Study:

• To evaluate the immunogenicity of a two-dose influenza A/H1N1 vaccine regimen in children with Down syndrome.
• To assess antibody titers against influenza A/H1N1 in this specific pediatric cohort.

Main Methods:

• A cohort of 48 children with Down syndrome received two doses of the influenza A/H1N1 vaccine.
• Hemagglutination-inhibition (HAI) titers were measured post-vaccination.
• Protective antibody levels were defined as HAI titers ≥1:40 and ≥1:110.

Main Results:

• 92% of children achieved a protective hemagglutination-inhibition titer of ≥1:40.
• Only 27% of children reached an HAI titer of ≥1:110, a level associated with 50% clinical protection.
• The study indicates a variable immune response to the influenza A/H1N1 vaccine in this population.

Conclusions:

• While a majority of Down syndrome children develop protective antibodies after two doses of influenza A/H1N1 vaccine, a smaller proportion reaches levels associated with robust clinical protection.
• Further research and potential adjustments to vaccination schedules may be necessary to optimize influenza A/H1N1 vaccine effectiveness in children with Down syndrome.